Dr. Zeta

Dr. Zeta is an innovative biotechnology company headquartered in Beijing, China, dedicated to the development of novel molecular glue degraders and targeted protein degradation (TPD) therapies. The company utilizes a proprietary AI-powered discovery platform to systematically identify and design small molecules that induce the degradation of disease-causing proteins, particularly those considered undruggable by traditional methods. Dr. Zeta's research and development efforts are primarily focused on oncology and autoimmune diseases, aiming to create high-efficacy, low-toxicity treatments. Supported by leading investors like GL Ventures and Matrix Partners China, the company is rapidly advancing its preclinical pipeline and expanding its technological capabilities in the field of induced proximity medicines. The firm represents a growing wave of Chinese biotech startups leveraging computational tools to accelerate the discovery of complex small molecule therapeutics.